Vir Biotechnology’s Second Act Comes With a Mask

A cancer drug that arrives wearing a mask sounds like a costume choice. At Vir Biotechnology, it is a business plan. The company is developing medicines designed to keep their immune-stimulating machinery shielded in circulation, then expose it inside a tumor. After the abrupt reversals of its pandemic years, Vir is trying to make selective activation work twice: in the molecule, and in the company’s spending.

The stakes are unusually legible. Vir paid $100 million upfront to license Sanofi’s oncology assets and masking technology in 2024. Another $75 million milestone followed in 2025. In 2026, Astellas became the partner for its prostate-cancer candidate. Alongside that wager sits a more advanced hepatitis delta program, approaching the clinical results that could determine whether Vir’s second act becomes a lasting business.

Vir is a drug developer with an immunology specialty. It designs and tests antibodies, combines different ways of interrupting disease, and brings outside inventions into its own pipeline. Patients are the intended beneficiaries. Pharmaceutical companies buying rights, sharing costs and preparing commercial launches are its immediate business counterparties. That distinction explains both its ambition and its accounts.

First came the antibodies. Then came the reversals.

Vir’s origin was closer to assembling a scientific network than building around one laboratory discovery. Incorporated in 2016, it launched publicly in January 2017 under former Biogen chief George Scangos. Founder Robert Nelsen and ARCH Venture Partners supplied the organizing force. ARCH committed $150 million, and the Gates Foundation was among the early backers.

By October 2017, Vir reported more than $500 million in financing to date. It had acquired Swiss antibody specialist Humabs BioMed and secured agreements with Alnylam and Visterra. Buying and licensing science was built into the original design. Its October 2019 IPO raised about $143 million gross in the base offering, selling shares at $20 each.

COVID-19 made that architecture useful at extraordinary speed. GSK joined Vir in 2020, committing a $250 million equity investment alongside their coronavirus collaboration. The partnership combined antibody discovery with the resources of a large pharmaceutical company. Sotrovimab received U.S. emergency authorization in May 2021 for certain patients at high risk of progressing to severe COVID-19.

The first major reversal in this story came from viral evolution. By April 5, 2022, the FDA said sotrovimab was no longer authorized in any U.S. region: the authorized dose was unlikely to work against the increasingly prevalent Omicron BA.2 subvariant. A medicine could meet an urgent need and still lose its usefulness against a changing target.

A separate disappointment arrived in July 2023. Vir’s PENINSULA trial of VIR-2482 for influenza prevention missed its primary and secondary efficacy endpoints. The company had just appointed Marianne De Backer as CEO that April. The setback did not prove every antiviral antibody would fail. It did make clear that a promising platform could not substitute for a successful trial.

A smaller company buys a different future

De Backer brought experience on both sides of the laboratory door. She started in drug discovery, later held business-development roles at Johnson & Johnson, and led pharmaceutical strategy and licensing at Bayer. Her background matters here because Vir’s reset required choosing assets, negotiating rights and deciding which research the company would stop paying for.

In August 2024, Vir announced plans to phase out influenza, COVID-19 and its T-cell-based viral-vector platform, alongside approximately 140 job reductions, roughly a quarter of the workforce at the time. The retrenchment coincided with the Sanofi license. This was a reallocation of money and scientific attention with a human cost attached.

Culture claims deserve that context. Vir calls its employees “Virites” and says all U.S. salary ranges are shared internally. Its careers page describes unaccrued time off and wellness support. Those are concrete employment practices; they cannot tell an outsider how it felt to work through the restructuring. The declared benefits and the disclosed cuts belong in the same portrait.

The mask is meant to buy a wider margin of safety

T-cell engagers bring immune cells into contact with cancer cells. The difficulty is getting that interaction where it is wanted. A target found on a tumor may also appear on healthy tissue, and an immune response outside the intended site can cause harm. Potency alone is therefore an incomplete selling point.

Vir’s licensed PRO-XTEN approach adds a physical shield. Its linkers are designed to be cut by proteases active in the tumor environment, releasing the mask and allowing the drug to act. The mask also extends circulation time; the unmasked molecule is intended to clear more rapidly. These are design goals whose practical value must be established in patients.

The three candidates put that concept against different targets: VIR-5500 against PSMA in prostate cancer, VIR-5818 against HER2, and VIR-5525 against EGFR. All were in Phase 1 development in Vir’s August 2026 update. They are experimental medicines, not a menu of cancer treatments available for routine prescribing.

The competitive claim is specific: shielding could let clinicians use immune-engaging drugs against targets whose toxicity has limited earlier approaches. If the mask releases in the wrong place, fails to release sufficiently in a tumor, or cannot deliver a useful balance of activity and tolerability, the proposition weakens. A memorable mechanism is not clinical differentiation by itself.

The other bet needs two injections

Vir’s nearest major clinical test is in chronic hepatitis delta, a serious liver infection that depends on hepatitis B. The treatment combines tobevibart, a neutralizing antibody, with elebsiran, an Alnylam-licensed small interfering RNA designed to reduce production of hepatitis B surface antigen. That protein is part of the machinery hepatitis delta relies on.

The idea is to interfere at more than one point in the viral life cycle. Vir is studying the combination as two sequential injections under the skin each month. Its ECLIPSE program includes two Phase 3 studies and a Phase 2b comparison with bulevirtide, with questions spanning initial treatment and switching from an existing therapy.

Those questions became commercially sharper in May 2026, when the FDA approved Gilead’s Hepcludex, or bulevirtide-gmod, for adults with chronic hepatitis delta without cirrhosis or with compensated cirrhosis. Vir is now pursuing a U.S. market with an approved rival. Hepcludex is administered daily; Vir’s monthly schedule is a potential practical distinction, not evidence of better efficacy.

Gilead’s accelerated approval also illustrates the gap between viral markers and long-term outcomes: improved disease-related clinical outcomes have not yet been established for Hepcludex. For any new entrant, the important questions extend beyond reducing a laboratory measurement. Patients and physicians need to know how well a treatment works over time, how tolerable it is, and what treatment demands of everyday life.

“we want to give the immune system tools to fight disease”

Marianne De Backer / BioTech Nation, 2024

Read the cheque before reading the headline

The Astellas agreement announced in February 2026 attached a $335 million upfront-and-near-term figure to VIR-5500. That number contains three different things: $240 million in upfront cash, a $75 million equity investment and a conditional $20 million manufacturing technology-transfer milestone. The first two were received in the second quarter. The third is tied to work still to be completed.

Astellas leads U.S. commercialization, with Vir retaining an option to co-promote, and holds exclusive commercial rights outside the United States. The arrangement provides an equal U.S. profit-and-loss split and royalties on sales elsewhere. It gives Vir an oncology partner while requiring it to share the economics of success.

Norgine performs a different role for the hepatitis delta combination. Its December 2025 agreement covers Europe, Australia and New Zealand. Vir received €55 million as an initial reimbursement of development costs, with up to €495 million in contingent milestones and royalties beyond that. Norgine also contributes approximately a quarter of future external costs for the ongoing ECLIPSE trials.

That structure explains a seemingly odd business fact: a company can generate substantial revenue before its current lead medicines are approved. Vir reported $68.6 million of revenue in 2025, largely driven by the Norgine payment. These are licensing economics. They should not be mistaken for repeat prescriptions or a stable stream of product demand.

What travels beyond Vir’s laboratory

The transferable lesson is to connect each partnership to a missing capability. GSK supplied scale for the coronavirus effort. Sanofi supplied oncology assets and technology. Astellas and Norgine bring commercial reach in different markets. Readers running smaller businesses can copy the question behind those arrangements: which job needs doing, and who already knows how to do it?

Vir’s internal AI platform offers another usable idea. Called dAIsY, for data, AI, structure and antibody, it links computational molecule design with laboratory testing and feeds experimental results into subsequent rounds. The useful habit is closing that feedback loop. A prediction earns its place by helping an experiment, and an experiment improves the next prediction.

Neither lesson travels without conditions. Licensing needs enough money to develop what is bought, people who can evaluate the science, and agreements that leave workable economics. Computational optimization needs relevant experimental feedback. A company with little capital or weak laboratory capabilities could reproduce the spending while missing the reason it might pay off.

The next verdict comes from the clinic

Vir’s August update put the first ECLIPSE Phase 3 results in the fourth quarter of 2026, with the other two trials expected in early 2027. It also reported about $1.01 billion in cash, cash equivalents and investments at June’s end. Management projected funding into the second half of 2028 under current operating plans.

For patients, the practical route to Vir’s investigational treatments is a discussion with a treating specialist about eligible studies, rather than an order from the company. For prospective partners, the attraction is a pipeline with defined biological targets and trial programs. Both groups ultimately need the same thing: evidence strong enough to justify the next decision.

Vir has changed the research it funds, bought new capabilities and found partners willing to write substantial cheques. Those decisions have created room to test the second act. Whether its masked medicines and hepatitis combination deserve a place in clinical practice remains a question the company cannot negotiate its way around.